Zacks Research Issues Positive Estimate for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now expects that the biotechnology company will earn $0.47 per share for the quarter, up from their prior forecast of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). The firm had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Other analysts have also issued reports about the stock. Truist Financial upped their price objective on Corcept Therapeutics from $76.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 31st. HC Wainwright increased their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 31st. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. StockNews.com lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Piper Sandler raised their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a report on Thursday, April 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $143.25.

Corcept Therapeutics Price Performance

NASDAQ CORT opened at $70.49 on Monday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $65.48 and a two-hundred day moving average price of $57.03. The stock has a market cap of $7.44 billion, a price-to-earnings ratio of 55.94 and a beta of 0.15. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $117.33.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CORT. Norges Bank bought a new stake in shares of Corcept Therapeutics during the fourth quarter worth $42,055,000. GAMMA Investing LLC lifted its holdings in Corcept Therapeutics by 12,888.9% during the 1st quarter. GAMMA Investing LLC now owns 389,148 shares of the biotechnology company’s stock worth $44,448,000 after buying an additional 386,152 shares in the last quarter. Braun Stacey Associates Inc. acquired a new position in Corcept Therapeutics during the 4th quarter worth $14,935,000. Synergy Asset Management LLC boosted its position in Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after buying an additional 262,503 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Corcept Therapeutics in the 4th quarter valued at $12,084,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Corcept Therapeutics

In related news, insider Sean Maduck sold 18,303 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.69, for a total value of $1,110,809.07. Following the sale, the insider now owns 85,622 shares of the company’s stock, valued at $5,196,399.18. The trade was a 17.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $68.08, for a total value of $149,776.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 163,124 shares of company stock worth $15,074,318. 20.50% of the stock is currently owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.